- Mycenax Biotech Inc. has entered into a non-binding term sheet with Alfresa Holdings, Kidswell Bio, and Chiome Bioscience to explore a joint venture in Japan for biopharmaceutical manufacturing.
- The JV aims to establish a GMP facility with Drug Substance (DS) and Drug Product (DP) capabilities, expanding Mycenax’s biologics CDMO and distribution business while supporting domestic biosimilar production.
Mycenax Biotech Inc. has signed a non-binding term sheet with Japanese partners Alfresa Holdings Corporation, Kidswell Bio Corporation, and Chiome Bioscience Inc. The agreement marks the start of discussions to establish a joint venture in Japan focused on biopharmaceutical GMP manufacturing, including both Drug Substance (DS) and Drug Product (DP) capabilities, alongside expanded biologics CDMO and distribution services.
The joint venture aligns with Japan’s “Subsidy Program for the Development of Domestic Manufacturing Facilities for Biosimilars,” promoted by the Ministry of Health, Labour and Welfare (MHLW). The program seeks to create a stable domestic supply chain for biosimilars, and the three Japanese partners have been approved for the subsidy, with Mycenax serving as a key collaborator.
Each partner brings complementary expertise to the initiative. Alfresa offers pharmaceutical distribution resources, Kidswell provides experience in biosimilar development and commercialisation, Chiome contributes novel biologics R&D capabilities, and Mycenax delivers process development, manufacturing expertise, and proven CDMO services. Chairman Pei-Jiun Chen noted that Mycenax has a long-standing presence in Japan and collaborates effectively with biopharma and biotech companies.
Currently, Mycenax is the commercial supplier of two internationally approved biologics. Through this joint venture, the company aims to strengthen its Japanese market foundation and provide integrated, end-to-end manufacturing options for clients. The initiative also reflects Mycenax’s focus on technological innovation, global expansion, and long-term competitiveness in the biologics CDMO sector.
